Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Her2+ • Journal Club ft. NEJM publications • Breast Cancer, Metastatic
Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts?
Are there other toxicities of concern given anticipated long term use of therapy?
Answer from: Medical Oncologist at Academic Institution
The most important strategy is global awareness of ILD as a potentially serious complication that may initially present with subtle signs. Patients and all care team members must not only be aware but remind others in the patient/family care circle. This needs to be reinforced regularly. The recogni...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
At the time being, we do not have specific strategies to mitigate the risk of developing ILD/pneumonitis while using T-DXd. In my opinion, we need prospective data to try to prevent this adverse event which has been reported in the range of 10.5% of patients. However, this event is not unique, and i...
Comments
Medical Oncologist at Indiana University School of Medicine
Awareness is key for detecting clinically signific...
Awareness is key for detecting clinically signific...
Answer from: Medical Oncologist at Community Practice
Pulmonary toxicity of T-DXd may represent off-target toxicity, as other DXd-based ADCs, anti-Trop2 datopotamab deruxtecan, and the anti-HER3 patritumab deruxtecan are capable of inducing ILD. The impact of an increased understanding of T–DXd–related ILD will likely extend beyond breast o...